SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-001115
Filing Date
2022-02-14
Accepted
2022-02-14 16:41:37
Documents
13
Period of Report
2022-02-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aytu-20220214x8k.htm   iXBRL 8-K 36244
2 EX-99.1 aytu-20220214xex99d1.htm EX-99.1 217053
  Complete submission text file 0001558370-22-001115.txt   389301

Data Files

Seq Description Document Type Size
3 EX-101.SCH aytu-20220214.xsd EX-101.SCH 3046
4 EX-101.LAB aytu-20220214_lab.xml EX-101.LAB 15933
5 EX-101.PRE aytu-20220214_pre.xml EX-101.PRE 10064
7 EXTRACTED XBRL INSTANCE DOCUMENT aytu-20220214x8k_htm.xml XML 4855
Mailing Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112
Business Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

IRS No.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 22633473
SIC: 2834 Pharmaceutical Preparations